Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 18/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31034784 | 0.74 | CYP11B2 (0.46) | CYP11B2TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL9123926 | 0.74 | TBXAS1 (0.49) | CYP11B2TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL20295391 | 0.74 | CYP11B2 (0.46) | CYP11B2TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL20295331 | 0.69 | TBXAS1 (0.49) | CYP11B2TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10645381 | 0.69 | TBXAS1 (0.56) | CYP11B2TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL20295359 | 0.69 | TBXAS1 (0.57) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10649907 | 0.69 | TBXAS1 (0.57) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL29951523 | 0.69 | TBXAS1 (0.45) | CYP11B2TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10648586 | 0.69 | TBXAS1 (0.57) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL19915749 | 0.69 | IDO1 (0.49) | CYP11B2TBXAS1PTGS1PTGS2PTGIS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023081666-A1 | COMPOUNDS AS CCR2 MODULATORS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081666-A1 | COMPOUNDS AS CCR2 MODULATORS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| WO-2021055591-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2018036414-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 北京诺诚健华医药科技有限公司 | 2018-03-01 | — | — | WO | disclosed |
| US-9340529-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-8802864-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| EP-2538787-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-12-13 | — | — | US | disclosed |
| EP-2493310-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011103546-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | CYP11B2 607/4885TBXAS1 80/4885PTGS1 362/4885 |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | IDO1, TDO2, IDO2 | CYP11B2 44/4885TBXAS1 1000/4885PTGS1 1212/4885 |
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | CYP11B2 390/4885TBXAS1 22/4885PTGS1 359/4885 |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | CYP11B2 182/4885TBXAS1 23/4885PTGS1 249/4885 |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | IDO1, IDO2, INMT | CYP11B2 45/4885TBXAS1 1113/4885PTGS1 466/4885 |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | CYP11B2 2960/4885TBXAS1 2218/4885PTGS1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.